PTD-DBM

What Is PTD-DBM?

PTD-DBM is a synthetic peptide designed to block the binding of CXXC-type zinc finger protein 5 (CXXC5) to Dishevelled (Dvl), a step that dampens Wnt/β-catenin signaling. Its name stands for protein transduction domain–Dvl-binding motif, and it was described as a competitor peptide that blocks CXXC5–Dvl interactions.^[1]

CXXC5 was characterized as a negative-feedback regulator of the Wnt/β-catenin pathway that acts through its interaction with Dvl.^[1][2] By interfering with that interaction, PTD-DBM activates Wnt/β-catenin signaling in experimental systems.^[1][3]

The pathway it targets is central to both of its main research areas. Wnt/β-catenin signaling plays important roles in cutaneous wound healing and dermal fibrosis,^[1] and it has been implicated in hair follicle development and in hair regeneration in adults.^[4] A 2025 review summarized studies showing that stimulating this pathway leads to hair follicle growth, while inhibiting it prompts follicle regression.^[5]

Research on the peptide has centered on skin wound healing, hair regrowth and wound-induced hair follicle neogenesis in mice, supported by cell-culture work. None of the studies summarized on this page report data from human trials of PTD-DBM.

Chemical Structure and Molecular Identity

PTD-DBM is a 25-residue linear peptide with the molecular formula C124H225N61O28S2 and a molecular weight of 3082.6, according to its PubChem record (CID 176453931). Its CAS number is 1609454-11-6.

Read from the N-terminus, the PubChem structure consists of eight arginines, four glycines, and a 13-residue segment (RKTGHQICKFRKC) that ends in a free carboxylic acid. Published papers describe the molecule as a protein transduction domain fused to a Dvl-binding motif.^[6] The arginine-rich N-terminal block and glycine spacer precede the remaining residues.

The sequence contains ten arginines and three lysines, which makes the molecule strongly basic and highly polar; PubChem lists a computed XLogP of −19.3. Its two cysteine residues are drawn as free thiols in the record.

Identifiers

• Formula: C124H225N61O28S2
• Molecular weight: 3082.6
• CAS: 1609454-11-6
• InChIKey: IMXABKONEGYGRF-QAMUXZJLSA-N
• Expanded name: protein transduction domain–Dishevelled-binding motif peptide

Research History and Development

PTD-DBM came out of a research program that identified CXXC5 as a Dvl-binding brake on Wnt/β-catenin signaling in bone, skin and hair. The peptide was developed as a tool to break that interaction and test what happens when the brake is removed.

In 2015, one study characterized CXXC5 as a negative regulator of osteoblast differentiation and bone formation and reported that a competitor peptide suppressing the Dvl–CXXC5 interaction activated the pathway, although the abstract refers to it only as a competitor peptide.^[2] A second 2015 study, on cutaneous wound healing, named the peptide PTD-DBM; its authors noted that no commercially available wound-healing agent targeting the Wnt/β-catenin pathway existed at the time.^[1] A 2023 hair-loss study described PTD-DBM as a peptide that activates the Wnt/β-catenin pathway by interfering with the Dvl-binding function of CXXC5.^[3] Across these papers, the work extended the approach to hair regrowth, prostaglandin D2 (PGD2)-related hair loss and scar-limiting wound patches.^[3][4][6]

Mechanisms Studied in Research

PTD-DBM competes with CXXC5 for binding to Dishevelled, which removes a negative-feedback brake and allows Wnt/β-catenin signaling to proceed.^[1]

The CXXC5–Dvl feedback loop

In osteoblast studies, CXXC5 was induced by Wnt/β-catenin signaling and bound Dvl in a Wnt-dependent manner, feeding back to suppress the pathway.^[2] In skin, CXXC5 protein levels were lower in epidermal keratinocytes and dermal fibroblasts of acute human wounds, and overexpression and silencing experiments pointed to a role in myofibroblast differentiation and collagen production.^[1]

Effects of blocking the interaction

In vitro, PTD-DBM disrupted the CXXC5 feedback loop and increased β-catenin and collagen production.^[1] In human hair follicle dermal papilla cells, CXXC5 suppressed alkaline phosphatase activity and cell proliferation, and disrupting the CXXC5–Dvl interaction activated Wnt/β-catenin signaling.^[4] In the same study, valproic acid further induced hair regrowth in CXXC5-knockout mice.^[4]

Pairing with GSK3β inhibition

Several studies combined PTD-DBM with valproic acid, a glycogen synthase kinase 3β (GSK3β) inhibitor that also activates the Wnt/β-catenin pathway.^[1][6] In a hair-loss model, inhibiting both GSK3β and CXXC5 function alleviated dihydrotestosterone (DHT)-induced hair loss.^[3]

The DHT–PGD2 axis

One study placed CXXC5 downstream of PGD2, a known alopecia inducer, and reported that CXXC5 also mediates DHT-induced hair loss through PGD2.^[3]

Key Findings From Published Studies

In mouse models, PTD-DBM accelerated wound healing, hair regrowth and wound-induced hair follicle neogenesis, and in combination with valproic acid it reduced scar formation. All of these findings are preclinical.

Cutaneous wound healing

Mice lacking CXXC5 healed skin wounds faster, with enhanced keratin 14 and collagen synthesis. Co-treating skin wounds with PTD-DBM and valproic acid synergistically accelerated cutaneous wound healing in mice.^[1]

Hair regrowth and follicle neogenesis

CXXC5 was upregulated in miniaturized hair follicles and arrector pili muscles of human balding scalps. CXXC5-knockout mice showed accelerated hair regrowth, and disrupting the CXXC5–Dvl interaction with a competitor peptide accelerated both hair regrowth and wound-induced hair follicle neogenesis in mice.^[4]

PGD2-induced hair loss

Hair loss induced by PGD2 in mice was restored by PTD-DBM treatment or by Cxxc5 knockout. In the wound-induced hair neogenesis model, PTD-DBM also overcame PGD2’s suppression of new hair growth.^[3]

Scar attenuation

Pyrogallol-functionalized hyaluronic acid (HA-PG) adhesive patches loaded with PTD-DBM and valproic acid significantly inhibited scar formation during wound healing in mice. Patches carrying PTD-DBM and/or valproic acid reduced the differentiated-cell marker α-smooth muscle actin, increased the stem cell markers CD105 and Nestin, and induced collagen III, a factor linked to regenerative healing. The authors noted that this collagen III induction paralleled what they observed in valproic acid-treated fibroblasts from Cxxc5-knockout mice.^[6]

Bone

Blocking the Dvl–CXXC5 interaction with a competitor peptide promoted osteoblast differentiation and accelerated thickness growth of cultured mouse calvariae (skull bones) ex vivo. In the same work, mice lacking CXXC5 had elevated bone mineral density without severe gross developmental abnormalities.^[2]

Because PTD-DBM is a 25-residue, arginine-rich peptide, confirming each lot’s sequence identity and purity by HPLC and mass spectrometry certificates of analysis matters.

Because PTD-DBM is a 25-residue, arginine-rich peptide, confirming each lot's sequence identity and purity by HPLC and mass spectrometry certificates of analysis matters.

Regulatory and Research Status

PTD-DBM is an experimental research peptide. It is not approved by the FDA for any use, and the studies summarized here do not include human trial results for it.

A 2025 review grouped PTD-DBM with small molecules and other agents that act on the Wnt/β-catenin pathway in hair follicle research. The authors noted that such approaches still require further research to validate their efficacy and to clarify their risk profile.^[5]

The primary studies framed the CXXC5–Dvl interaction as a research target for wound healing and hair loss rather than reporting clinical outcomes.^[1][4] Most of them share authors, and the evidence rests on cell culture, ex vivo tissue and mouse models.